Results 1 to 10 of about 4,092 (142)

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study. [PDF]

Arthritis Rheumatol
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Scher JU, McInnes IB, Soriano ER, Merola JF, Bird P, Chandran V, Cheng E, Reynoso E, Chen W, Li M, Gensler LS, Mease PJ, Ritchlin CT.   +12 more
europepmc   +2 more sources

Guselkumab for Hidradenitis Suppurativa in a Patient With Concomitant Crohn’s Disease: Report and Systematic Literature Review of Effectiveness and Safety

Clinical Case Reports (discontinued), 2020
Guselkumab appears to be safe and effective in the treatment of patients with HS, who do not respond to adalimumab and other systemic therapies. Guselkumab can be used in patients with comorbid Crohn's disease.
Astrid-Helene Ravn Jørgensen, Simon Francis Thomsen, Jesper Grønlund Holm   +2 more
exaly   +2 more sources

Efficacy and safety of Guselkumab for moderate-to-severe psoriasis: A systematic review and meta-analysis of randomized controlled trials [PDF]

Dermatology Practical & Conceptual
Introduction: Psoriasis, a chronic inflammatory skin condition, affects 125 million worldwide. Current treatments provide symptomatic relief but face limitations. Guselkumab shows promise for moderate-to-severe psoriasis.
Laura Ghanem, Antonia Moubarak, Jacinthe Khater, Ibrahim A. Yakout, Virginia Velasco-Tamariz   +4 more
doaj   +2 more sources

Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis. [PDF]

Int J Dermatol
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Falco GM, Ippoliti E, Gori N, Caldarola G, De Simone C, Di Giorgi N, Longo PG, Galluzzo M, Bianchi L, Marcelli L, Talamonti M, Cannizzaro MV, Di Nardo L, Peris K.   +13 more
europepmc   +2 more sources

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis

Clinical and Translational Science, 2022
Guselkumab is an anti‐interleukin‐23 human monoclonal antibody effective in treating psoriatic arthritis (PsA). To characterize the pharmacokinetics (PKs) and exposure‐response relationship of guselkumab in PsA, population PKs, and exposure‐response ...
Yang Chen, Xin Miao, Chyi‐Hung Hsu, Yanli Zhuang, Alexa Kollmeier, Zhenhua Xu, Honghui Zhou, Amarnath Sharma   +7 more
doaj   +1 more source

Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial

Arthritis Research & Therapy, 2023
Background Nail psoriasis is a common, physiologically, and psychologically disruptive, and yet often under-treated manifestation of psoriasis. The objectives of this analysis were to investigate the trajectory of nail psoriasis, a risk factor for ...
William Tillett, Alexander Egeberg, Enikö Sonkoly, Patricia Gorecki, Anna Tjärnlund, Jozefien Buyze, Sven Wegner, Dennis McGonagle   +7 more
doaj   +1 more source

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

Acta Dermato-Venereologica, 2022
Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year.
Tarja Mälkönen, Pauliina Nuutinen, Taru Hallinen, Erkki Soini, Riikka Nissinen, Christina Wennerstöm, Tapio Rantanen, Johanna H. Hagman, Rauno Harvima, Johanna Höök-Nikanne, Tiina Ilves, Päivi Lintu, Ken Malanin, Iina Soramäki, Kaisa Tasanen, Arja Teho, Katja Vähävihu, Sari Itälinna, Pekka Leinonen, Piia Sarajärvi, Laura Huilaja, Rafael Pasternack   +21 more
doaj   +1 more source

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade

Vestnik Dermatologii i Venerologii, 2020
Materials and methods. In this paper, we review publications on the significance of interleukin-(IL)-23 in the pathogenesis of plaque psoriasis and analyse the results of the 1st and 2nd phase clinical studies, as well as the 3rd phase comparative ...
V. V. Chikin
doaj   +1 more source

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

RMD Open, 2021
Objective To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment.Methods Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1 and DISCOVER-2 studies.
Kristen Sweet, Matthew J Loza, Philip Cooper, Qingxuan Song, Keying Ma, Karen Leander, Vani Lakshminarayanan, Carol Franks   +7 more
doaj   +1 more source

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

RMD Open, 2020
Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA).Methods This was a phase II, randomised, placebo-controlled, double-blind trial of adults with active PsA ...
Peter Nash, Atul Deodhar, Philip J Mease, Dafna D Gladman, Philip S Helliwell, Dennis G McGonagle, Alice Gottlieb, Elizabeth C Hsia, Chetan S Karyekar, Wolf-Henning Boehncke, Xie L Xu, Stephen Xu   +11 more
doaj   +1 more source